Title

Exercise medicine for the management of androgen deprivation therapy-related side effects in prostate cancer

Document Type

Journal Article

Publication Title

Urologic Oncology: Seminars and Original Investigations

Publisher

Elsevier

School

Exercise Medicine Research Institute

Comments

Cormie, P., & Zopf, E. M. (2020). Exercise medicine for the management of androgen deprivation therapy-related side effects in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 38(2), 62-70. https://doi.org/10.1016/j.urolonc.2018.10.008

Abstract

Androgen deprivation therapy (ADT) is associated with considerable adverse side effects which compromise the health and wellbeing of many men with prostate cancer. Exercise has been identified as a therapy to help manage ADT-related treatment toxicities. This paper systematically journalarticles the scientific literature investigating the impact of exercise on men receiving ADT and discusses strategies to effectively implement exercise in clinical practice. The findings of this journalarticle demonstrate that exercise has therapeutic benefit for the management of ADT-related side effects. Significant positive effects following exercise were observed for aerobic fitness, muscular strength, physical function, body composition, fatigue, sexual wellbeing, mental wellbeing, social function, comorbid disease risk factors, and quality of life. Emerging evidence suggests exercise may also play a role in managing bone loss, cognitive decline, and urinary problems, and may be delivered without exacerbating bone pain. Exercise did not negatively influence ADT treatment efficacy and led to few adverse events of minor severity, rendering it a safe intervention for men receiving ADT. To maximize the therapeutic effect of exercise, men with prostate cancer should participate in moderate-to-high intensity aerobic, resistance and impact exercise which is prescribed and supervised by a qualified exercise physiologist and delivered at a convenient location in a prostate cancer specific group-based environment. The level of evidence now available supports the view that the prescription of exercise medicine should be part of routine prostate cancer care.

DOI

10.1016/j.urolonc.2018.10.008

Share

 
COinS